Form 4: Haemonetics Director Acquires Restricted Stock Units

Haemonetics Corp. Director Charles J. Dockendorff acquired 2,693 restricted stock units as part of the company's long-term incentive plan.

Summary

• Charles J. Dockendorff, a Director of Haemonetics Corp. (HAE), acquired 2,693 shares of common stock on July 24, 2025.
• The acquired securities are in the form of Restricted Stock Units (RSUs) issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
• The RSUs will vest 100% on the first anniversary of the grant date.
• Following this transaction, Mr. Dockendorff's direct beneficial ownership of common stock is 7,126 shares.
• Additionally, Mr. Dockendorff holds an indirect beneficial ownership of 17,915 shares through a Spouse's Revocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a director's continued alignment with the company's performance through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The acquisition of Restricted Stock Units (RSUs) by a director aligns their interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The issuance of RSUs is part of a structured long-term incentive compensation plan, indicating a commitment to retaining and incentivizing key personnel.

Negatives

• The issuance of new shares upon RSU vesting could lead to minor dilution for existing shareholders, although this is a standard component of equity compensation plans.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the vesting schedule of the granted RSUs.

Industry Context

This filing represents a routine insider transaction related to executive compensation within the medical technology industry. Such grants are common practice to incentivize and retain directors and executives, aligning their financial interests with the company's long-term performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of long-term incentive compensation is a common practice across various industries, including medical technology, aligning with global benchmarks for executive remuneration.
• The vesting schedule of 100% on the first anniversary of the grant date is a typical structure for director RSU grants, similar to practices observed at comparable companies like Medtronic (MDT) or Abbott Laboratories (ABT) for non-employee director compensation.

Corporate Governance

Related Party Transactions

• The transaction involves a director of the company acquiring equity, which is a common form of related party transaction in the context of executive and director compensation.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders through equity ownership, potentially fostering long-term value creation. However, it also implies future minor dilution upon RSU vesting.
• Employees: While not directly impacting all employees, the use of a long-term incentive plan for directors can signal a broader commitment to performance-based compensation within the company.

Next Steps

• The 2,693 Restricted Stock Units (RSUs) are expected to vest 100% on the first anniversary of the grant date (July 24, 2025), at which point they will convert into shares of Haemonetics Corp. common stock.

Key Dates

Keywords

Haemonetics Corp, HAE, Restricted Stock Units, RSUs, Insider Transaction, Form 4, Beneficial Ownership, Director Compensation, Equity Compensation, Long-Term Incentive Plan